Bold claim first: a simple blood test could reveal how severely the brain has been affected after a cardiac arrest. This new biomarker approach, not yet used in standard cardiac arrest care, offers a clearer read on brain injury and could guide how aggressively patients are treated in the ICU. A large international study led by researchers at Lund University and published in The Lancet Respiratory Medicine supports this potential breakthrough. Worldwide, around four million people suffer a sudden cardiac arrest each year.
This work suggests a future where a quick blood test helps clinicians determine a patient’s realistic chances of meaningful recovery. If results indicate a real likelihood of waking and regaining independence, continued intensive care becomes a more confident option. If, on the other hand, the test points to a very low chance of a good functional outcome, clinicians and families might consider shifting toward comfort-focused care. This nuanced guidance could spare patients from prolonged, non-beneficial treatments while focusing resources on those with better prospects.
The multicenter study compared four brain damage biomarkers to see which most accurately estimates the extent of brain injury in unconscious patients after a cardiac arrest. Lead author Niklas Nielsen, professor of anaesthesiology and intensive care at Lund University and a clinician at Helsingborg Hospital, explains that while all ICU patients post-arrest are unconscious, the jury is still out on how long to continue life-sustaining care. A reliable blood test that indicates a high likelihood of poor outcome can support timely transition to palliative planning, whereas a test signaling potential recovery supports ongoing intensive support.
Traditionally used biomarkers, neuron-specific enolase and S-100 protein, showed limitations for predicting brain damage after cardiac arrest. The study’s findings align with earlier, smaller studies by comparing four biomarkers using methods that can be implemented in everyday clinical practice. The standout biomarker is neurofilament light (NFL), which correctly identifies about 92% of six-month outcomes after cardiac arrest. NFL also differentiates better between major and minor brain injury and reaches predictive value as early as 24 hours after arrest. Additionally, NFL demonstrates greater stability in blood samples, aiding measurement reliability. Another biomarker in the mix, GFAP (glial fibrillary acidic protein), performed better than some current clinical markers in estimating the extent of brain damage.
However, Nielsen cautions that a blood test alone cannot dictate a decision to end intensive care. Clinicians must integrate findings with other data, such as imaging results (X-rays) and brain electrical activity analyses, to form a complete prognosis.
Overall, these results offer a more reliable framework for assessing the probability of waking after a cardiac arrest, which could influence treatment decisions and family discussions in the ICU. The study involved 819 adult patients across 24 European hospitals. Blood samples were collected at 0, 24, 48, and 72 hours after hospital admission and analyzed using a single, standardized machine.
Contextual note: this research builds on the larger international TTM2 trial, which compared therapeutic cooling to normal temperature after out-of-hospital cardiac arrest. The TTM2 trial, published in NEJM in 2021, found no survival or functional advantage for cooling, which shifted international guidelines away from routine body cooling.
Source:
Journal reference:
